产业支付与多发性硬化品牌药处方在Medicare中的关联
本研究分析2021-2022年Open Payments与2022-2023年Medicare Part D数据,评估品牌药厂商支付与品牌格拉斯默和富马酸二甲酯处方比例的关系。结果显示接受≥$1,000支付与高品牌处方几率增加相关(格拉斯默aOR 4.21,富马酸二甲酯aOR 2.53)。
要点
- 接受≥$1,000支付与高品牌格拉斯默处方几率增加相关(aOR 4.21)。
- 接受≥$1,000支付与高品牌富马酸二甲酯处方几率增加相关(aOR 2.53)。
- 低于$1,000的支付也与更高品牌处方相关。
核心结论
- 产业支付与两种MS药物仿制药 uptake 降低相关,导致患者和美国医疗系统支出增加。
研究设计与样本
- 横断面研究,使用2021-2022年Open Payments数据和2022-2023年Medicare Part D处方数据。
- 纳入2,675名格拉斯默处方者和2,138名富马酸二甲酯处方者。
主要发现
- 1,026名(38.4%)格拉斯默处方者和1,238名(57.9%)富马酸二甲酯处方者接受了支付。
- 接受≥$1,000支付与高品牌格拉斯默处方几率增加相关(aOR 4.21,95%CI 1.81-9.81,p<0.001)。
- 接受≥$1,000支付与高品牌富马酸二甲酯处方几率增加相关(aOR 2.53,95%CI 1.57-4.07,p<0.001)。
- 低于$1,000的支付也与更高品牌处方相关。
临床怎么用
- 临床医生应意识到产业支付可能影响仿制药处方选择,促进使用低成本仿制药。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Industry payments to clinicians influence prescribing, limiting use of lower-cost generics, and leading to nonadherence. This study of prescribing for multiple sclerosis examined whether payments from brand-name drug manufacturers were associated with prescribing of brand-name glatiramer and dimethyl fumarate after generics became available. METHODS: This cross-sectional study used 2021-2022 Open Payments data and 2022-2023 Medicare Part D prescription data. Payments from Teva (glatiramer) and Biogen (dimethyl fumarate) were categorized as none, <$1,000, or ≥$1,000. The outcome was the proportion of brand-name prescriptions per clinician, categorized as low (<20%), medium (20%-79%), or high (≥80%). Associations were assessed using multinomial logistic regression, adjusting for prescriber type, prescription volume, and geographic region. RESULTS: Among 2,675 glatiramer and 2,138 dimethyl fumarate prescribers, 1,026 (38.4%) and 1,238 (57.9%) received payments, respectively. Receiving ≥$1,000 in payments was associated with a greater odds of high brand-name prescribing for glatiramer (adjusted odds ratio [aOR] 4.21, 95% CI 1.81-9.81, p < 0.001) and dimethyl fumarate (aOR 2.53, 95% CI 1.57-4.07, p < 0.001). Payments <$1,000 were also associated with higher brand-name prescribing. DISCUSSION: Payments to clinicians were associated with lower uptake of generic versions of 2 MS drugs, resulting in higher spending by patients and the US health care system.
引用
- Patel AN, Kesselheim AS, Rome BN, et al. Industry Payments and Prescribing of Brand-Name Multiple Sclerosis Medications in Medicare. Neurology. 2026. PMID: 41941704. doi:10.1212/WNL.0000000000214834
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。